* Zobrazit nápovědu

86 záznamů v Medvik Filtry

Článek

Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation

Healey, Jeff S
Autor Healey, Jeff S ORCID From the Population Health Research Institute, McMaster University, Hamilton, ON (J.S.H., W.F.M., D.C., J.A.W., L.X., K.S., S.N., R.M., S.J.C.), the Montreal Heart Institute, University of Montreal, Montreal (L.R.), the University of Ottawa Heart Institute, Ottawa (D.H.B.), Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Quebec, QC (F.P.), the Department of Clinical Neurosciences, Radiology, and Community Health Sciences, Hotchkiss Brain Institute, University of Calgary, Calgary, AB (S.B.C.), and the Université de Sherbrooke, Sherbrooke, QC (F.A.-P.) - all in Canada the Duke Clinical Research Institute, Duke University, Durham, NC (R.D.L., C.B.G.) Amphia Ziekenhuis, Breda, the Netherlands (M.A.) Oslo University Hospital and the University of Oslo, Oslo (D.A.) the University of Modena and Reggio Emilia, Modena (G.B.), and the Department of Clinical Sciences and Community Health, University of Milan, and the Division of Subacute Care, IRCCS Istituti Clinici Scientifici Maugeri, Milan (M. Proietti) - all in Italy St. George's, University of London, London (A.J.C.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - both in the United Kingdom J.W. Goethe University, University Hospital Department of Cardiology, Frankfurt, Germany (J.W.E., S.H.H.) the Medical University of South Carolina, Charleston (M.R.G.) Michigan State University, Lansing (J.I.) the Institute for Clinical and Experimental Medicine, Prague, Czech Republic (J.K.) the University of Rochester, Rochester, NY (V.K.) Semmelweis University, Budapest, Hungary (V.K.) Karolinska Institutet and the Heart, Vascular, and Neurology Theme, Karolinska University Hospital, Stockholm (C.L.) the University of Rennes, Rennes, France (P.M.) Cliniques du Sud-Luxembourg, Arlon, Belgium (G.M.) Hospital Universitario La Luz, Madrid (J.B.M.), and Hospital Costa del Sol, Marbella (M. Pombo) - both in Spain Aarhus University Hospital and Aarhus University, Aarhus, Denmark (J.C.N.) University Hospital Basel, University of Basel, Basel, Switzerland (C.S.) the Veterans Affairs Portland Health Care System, Portland, OR (I.G.Z.) and Abrazo Arrowhead Hospital, Glendale, AZ (A.K.)
Lopes, Renato D
Autor Lopes, Renato D From the Population Health Research Institute, McMaster University, Hamilton, ON (J.S.H., W.F.M., D.C., J.A.W., L.X., K.S., S.N., R.M., S.J.C.), the Montreal Heart Institute, University of Montreal, Montreal (L.R.), the University of Ottawa Heart Institute, Ottawa (D.H.B.), Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Quebec, QC (F.P.), the Department of Clinical Neurosciences, Radiology, and Community Health Sciences, Hotchkiss Brain Institute, University of Calgary, Calgary, AB (S.B.C.), and the Université de Sherbrooke, Sherbrooke, QC (F.A.-P.) - all in Canada the Duke Clinical Research Institute, Duke University, Durham, NC (R.D.L., C.B.G.) Amphia Ziekenhuis, Breda, the Netherlands (M.A.) Oslo University Hospital and the University of Oslo, Oslo (D.A.) the University of Modena and Reggio Emilia, Modena (G.B.), and the Department of Clinical Sciences and Community Health, University of Milan, and the Division of Subacute Care, IRCCS Istituti Clinici Scientifici Maugeri, Milan (M. Proietti) - all in Italy St. George's, University of London, London (A.J.C.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - both in the United Kingdom J.W. Goethe University, University Hospital Department of Cardiology, Frankfurt, Germany (J.W.E., S.H.H.) the Medical University of South Carolina, Charleston (M.R.G.) Michigan State University, Lansing (J.I.) the Institute for Clinical and Experimental Medicine, Prague, Czech Republic (J.K.) the University of Rochester, Rochester, NY (V.K.) Semmelweis University, Budapest, Hungary (V.K.) Karolinska Institutet and the Heart, Vascular, and Neurology Theme, Karolinska University Hospital, Stockholm (C.L.) the University of Rennes, Rennes, France (P.M.) Cliniques du Sud-Luxembourg, Arlon, Belgium (G.M.) Hospital Universitario La Luz, Madrid (J.B.M.), and Hospital Costa del Sol, Marbella (M. Pombo) - both in Spain Aarhus University Hospital and Aarhus University, Aarhus, Denmark (J.C.N.) University Hospital Basel, University of Basel, Basel, Switzerland (C.S.) the Veterans Affairs Portland Health Care System, Portland, OR (I.G.Z.) and Abrazo Arrowhead Hospital, Glendale, AZ (A.K.)
Granger, Christopher B
Autor Granger, Christopher B From the Population Health Research Institute, McMaster University, Hamilton, ON (J.S.H., W.F.M., D.C., J.A.W., L.X., K.S., S.N., R.M., S.J.C.), the Montreal Heart Institute, University of Montreal, Montreal (L.R.), the University of Ottawa Heart Institute, Ottawa (D.H.B.), Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Quebec, QC (F.P.), the Department of Clinical Neurosciences, Radiology, and Community Health Sciences, Hotchkiss Brain Institute, University of Calgary, Calgary, AB (S.B.C.), and the Université de Sherbrooke, Sherbrooke, QC (F.A.-P.) - all in Canada the Duke Clinical Research Institute, Duke University, Durham, NC (R.D.L., C.B.G.) Amphia Ziekenhuis, Breda, the Netherlands (M.A.) Oslo University Hospital and the University of Oslo, Oslo (D.A.) the University of Modena and Reggio Emilia, Modena (G.B.), and the Department of Clinical Sciences and Community Health, University of Milan, and the Division of Subacute Care, IRCCS Istituti Clinici Scientifici Maugeri, Milan (M. Proietti) - all in Italy St. George's, University of London, London (A.J.C.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - both in the United Kingdom J.W. Goethe University, University Hospital Department of Cardiology, Frankfurt, Germany (J.W.E., S.H.H.) the Medical University of South Carolina, Charleston (M.R.G.) Michigan State University, Lansing (J.I.) the Institute for Clinical and Experimental Medicine, Prague, Czech Republic (J.K.) the University of Rochester, Rochester, NY (V.K.) Semmelweis University, Budapest, Hungary (V.K.) Karolinska Institutet and the Heart, Vascular, and Neurology Theme, Karolinska University Hospital, Stockholm (C.L.) the University of Rennes, Rennes, France (P.M.) Cliniques du Sud-Luxembourg, Arlon, Belgium (G.M.) Hospital Universitario La Luz, Madrid (J.B.M.), and Hospital Costa del Sol, Marbella (M. Pombo) - both in Spain Aarhus University Hospital and Aarhus University, Aarhus, Denmark (J.C.N.) University Hospital Basel, University of Basel, Basel, Switzerland (C.S.) the Veterans Affairs Portland Health Care System, Portland, OR (I.G.Z.) and Abrazo Arrowhead Hospital, Glendale, AZ (A.K.)
Alings, Marco
Autor Alings, Marco From the Population Health Research Institute, McMaster University, Hamilton, ON (J.S.H., W.F.M., D.C., J.A.W., L.X., K.S., S.N., R.M., S.J.C.), the Montreal Heart Institute, University of Montreal, Montreal (L.R.), the University of Ottawa Heart Institute, Ottawa (D.H.B.), Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Quebec, QC (F.P.), the Department of Clinical Neurosciences, Radiology, and Community Health Sciences, Hotchkiss Brain Institute, University of Calgary, Calgary, AB (S.B.C.), and the Université de Sherbrooke, Sherbrooke, QC (F.A.-P.) - all in Canada the Duke Clinical Research Institute, Duke University, Durham, NC (R.D.L., C.B.G.) Amphia Ziekenhuis, Breda, the Netherlands (M.A.) Oslo University Hospital and the University of Oslo, Oslo (D.A.) the University of Modena and Reggio Emilia, Modena (G.B.), and the Department of Clinical Sciences and Community Health, University of Milan, and the Division of Subacute Care, IRCCS Istituti Clinici Scientifici Maugeri, Milan (M. Proietti) - all in Italy St. George's, University of London, London (A.J.C.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - both in the United Kingdom J.W. Goethe University, University Hospital Department of Cardiology, Frankfurt, Germany (J.W.E., S.H.H.) the Medical University of South Carolina, Charleston (M.R.G.) Michigan State University, Lansing (J.I.) the Institute for Clinical and Experimental Medicine, Prague, Czech Republic (J.K.) the University of Rochester, Rochester, NY (V.K.) Semmelweis University, Budapest, Hungary (V.K.) Karolinska Institutet and the Heart, Vascular, and Neurology Theme, Karolinska University Hospital, Stockholm (C.L.) the University of Rennes, Rennes, France (P.M.) Cliniques du Sud-Luxembourg, Arlon, Belgium (G.M.) Hospital Universitario La Luz, Madrid (J.B.M.), and Hospital Costa del Sol, Marbella (M. Pombo) - both in Spain Aarhus University Hospital and Aarhus University, Aarhus, Denmark (J.C.N.) University Hospital Basel, University of Basel, Basel, Switzerland (C.S.) the Veterans Affairs Portland Health Care System, Portland, OR (I.G.Z.) and Abrazo Arrowhead Hospital, Glendale, AZ (A.K.)
Rivard, Lena
Autor Rivard, Lena From the Population Health Research Institute, McMaster University, Hamilton, ON (J.S.H., W.F.M., D.C., J.A.W., L.X., K.S., S.N., R.M., S.J.C.), the Montreal Heart Institute, University of Montreal, Montreal (L.R.), the University of Ottawa Heart Institute, Ottawa (D.H.B.), Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Quebec, QC (F.P.), the Department of Clinical Neurosciences, Radiology, and Community Health Sciences, Hotchkiss Brain Institute, University of Calgary, Calgary, AB (S.B.C.), and the Université de Sherbrooke, Sherbrooke, QC (F.A.-P.) - all in Canada the Duke Clinical Research Institute, Duke University, Durham, NC (R.D.L., C.B.G.) Amphia Ziekenhuis, Breda, the Netherlands (M.A.) Oslo University Hospital and the University of Oslo, Oslo (D.A.) the University of Modena and Reggio Emilia, Modena (G.B.), and the Department of Clinical Sciences and Community Health, University of Milan, and the Division of Subacute Care, IRCCS Istituti Clinici Scientifici Maugeri, Milan (M. Proietti) - all in Italy St. George's, University of London, London (A.J.C.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - both in the United Kingdom J.W. Goethe University, University Hospital Department of Cardiology, Frankfurt, Germany (J.W.E., S.H.H.) the Medical University of South Carolina, Charleston (M.R.G.) Michigan State University, Lansing (J.I.) the Institute for Clinical and Experimental Medicine, Prague, Czech Republic (J.K.) the University of Rochester, Rochester, NY (V.K.) Semmelweis University, Budapest, Hungary (V.K.) Karolinska Institutet and the Heart, Vascular, and Neurology Theme, Karolinska University Hospital, Stockholm (C.L.) the University of Rennes, Rennes, France (P.M.) Cliniques du Sud-Luxembourg, Arlon, Belgium (G.M.) Hospital Universitario La Luz, Madrid (J.B.M.), and Hospital Costa del Sol, Marbella (M. Pombo) - both in Spain Aarhus University Hospital and Aarhus University, Aarhus, Denmark (J.C.N.) University Hospital Basel, University of Basel, Basel, Switzerland (C.S.) the Veterans Affairs Portland Health Care System, Portland, OR (I.G.Z.) and Abrazo Arrowhead Hospital, Glendale, AZ (A.K.)
McIntyre, William F
Autor McIntyre, William F From the Population Health Research Institute, McMaster University, Hamilton, ON (J.S.H., W.F.M., D.C., J.A.W., L.X., K.S., S.N., R.M., S.J.C.), the Montreal Heart Institute, University of Montreal, Montreal (L.R.), the University of Ottawa Heart Institute, Ottawa (D.H.B.), Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Quebec, QC (F.P.), the Department of Clinical Neurosciences, Radiology, and Community Health Sciences, Hotchkiss Brain Institute, University of Calgary, Calgary, AB (S.B.C.), and the Université de Sherbrooke, Sherbrooke, QC (F.A.-P.) - all in Canada the Duke Clinical Research Institute, Duke University, Durham, NC (R.D.L., C.B.G.) Amphia Ziekenhuis, Breda, the Netherlands (M.A.) Oslo University Hospital and the University of Oslo, Oslo (D.A.) the University of Modena and Reggio Emilia, Modena (G.B.), and the Department of Clinical Sciences and Community Health, University of Milan, and the Division of Subacute Care, IRCCS Istituti Clinici Scientifici Maugeri, Milan (M. Proietti) - all in Italy St. George's, University of London, London (A.J.C.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - both in the United Kingdom J.W. Goethe University, University Hospital Department of Cardiology, Frankfurt, Germany (J.W.E., S.H.H.) the Medical University of South Carolina, Charleston (M.R.G.) Michigan State University, Lansing (J.I.) the Institute for Clinical and Experimental Medicine, Prague, Czech Republic (J.K.) the University of Rochester, Rochester, NY (V.K.) Semmelweis University, Budapest, Hungary (V.K.) Karolinska Institutet and the Heart, Vascular, and Neurology Theme, Karolinska University Hospital, Stockholm (C.L.) the University of Rennes, Rennes, France (P.M.) Cliniques du Sud-Luxembourg, Arlon, Belgium (G.M.) Hospital Universitario La Luz, Madrid (J.B.M.), and Hospital Costa del Sol, Marbella (M. Pombo) - both in Spain Aarhus University Hospital and Aarhus University, Aarhus, Denmark (J.C.N.) University Hospital Basel, University of Basel, Basel, Switzerland (C.S.) the Veterans Affairs Portland Health Care System, Portland, OR (I.G.Z.) and Abrazo Arrowhead Hospital, Glendale, AZ (A.K.)
Atar, Dan
Autor Atar, Dan From the Population Health Research Institute, McMaster University, Hamilton, ON (J.S.H., W.F.M., D.C., J.A.W., L.X., K.S., S.N., R.M., S.J.C.), the Montreal Heart Institute, University of Montreal, Montreal (L.R.), the University of Ottawa Heart Institute, Ottawa (D.H.B.), Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Quebec, QC (F.P.), the Department of Clinical Neurosciences, Radiology, and Community Health Sciences, Hotchkiss Brain Institute, University of Calgary, Calgary, AB (S.B.C.), and the Université de Sherbrooke, Sherbrooke, QC (F.A.-P.) - all in Canada the Duke Clinical Research Institute, Duke University, Durham, NC (R.D.L., C.B.G.) Amphia Ziekenhuis, Breda, the Netherlands (M.A.) Oslo University Hospital and the University of Oslo, Oslo (D.A.) the University of Modena and Reggio Emilia, Modena (G.B.), and the Department of Clinical Sciences and Community Health, University of Milan, and the Division of Subacute Care, IRCCS Istituti Clinici Scientifici Maugeri, Milan (M. Proietti) - all in Italy St. George's, University of London, London (A.J.C.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - both in the United Kingdom J.W. Goethe University, University Hospital Department of Cardiology, Frankfurt, Germany (J.W.E., S.H.H.) the Medical University of South Carolina, Charleston (M.R.G.) Michigan State University, Lansing (J.I.) the Institute for Clinical and Experimental Medicine, Prague, Czech Republic (J.K.) the University of Rochester, Rochester, NY (V.K.) Semmelweis University, Budapest, Hungary (V.K.) Karolinska Institutet and the Heart, Vascular, and Neurology Theme, Karolinska University Hospital, Stockholm (C.L.) the University of Rennes, Rennes, France (P.M.) Cliniques du Sud-Luxembourg, Arlon, Belgium (G.M.) Hospital Universitario La Luz, Madrid (J.B.M.), and Hospital Costa del Sol, Marbella (M. Pombo) - both in Spain Aarhus University Hospital and Aarhus University, Aarhus, Denmark (J.C.N.) University Hospital Basel, University of Basel, Basel, Switzerland (C.S.) the Veterans Affairs Portland Health Care System, Portland, OR (I.G.Z.) and Abrazo Arrowhead Hospital, Glendale, AZ (A.K.)
Birnie, David H
Autor Birnie, David H From the Population Health Research Institute, McMaster University, Hamilton, ON (J.S.H., W.F.M., D.C., J.A.W., L.X., K.S., S.N., R.M., S.J.C.), the Montreal Heart Institute, University of Montreal, Montreal (L.R.), the University of Ottawa Heart Institute, Ottawa (D.H.B.), Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Quebec, QC (F.P.), the Department of Clinical Neurosciences, Radiology, and Community Health Sciences, Hotchkiss Brain Institute, University of Calgary, Calgary, AB (S.B.C.), and the Université de Sherbrooke, Sherbrooke, QC (F.A.-P.) - all in Canada the Duke Clinical Research Institute, Duke University, Durham, NC (R.D.L., C.B.G.) Amphia Ziekenhuis, Breda, the Netherlands (M.A.) Oslo University Hospital and the University of Oslo, Oslo (D.A.) the University of Modena and Reggio Emilia, Modena (G.B.), and the Department of Clinical Sciences and Community Health, University of Milan, and the Division of Subacute Care, IRCCS Istituti Clinici Scientifici Maugeri, Milan (M. Proietti) - all in Italy St. George's, University of London, London (A.J.C.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - both in the United Kingdom J.W. Goethe University, University Hospital Department of Cardiology, Frankfurt, Germany (J.W.E., S.H.H.) the Medical University of South Carolina, Charleston (M.R.G.) Michigan State University, Lansing (J.I.) the Institute for Clinical and Experimental Medicine, Prague, Czech Republic (J.K.) the University of Rochester, Rochester, NY (V.K.) Semmelweis University, Budapest, Hungary (V.K.) Karolinska Institutet and the Heart, Vascular, and Neurology Theme, Karolinska University Hospital, Stockholm (C.L.) the University of Rennes, Rennes, France (P.M.) Cliniques du Sud-Luxembourg, Arlon, Belgium (G.M.) Hospital Universitario La Luz, Madrid (J.B.M.), and Hospital Costa del Sol, Marbella (M. Pombo) - both in Spain Aarhus University Hospital and Aarhus University, Aarhus, Denmark (J.C.N.) University Hospital Basel, University of Basel, Basel, Switzerland (C.S.) the Veterans Affairs Portland Health Care System, Portland, OR (I.G.Z.) and Abrazo Arrowhead Hospital, Glendale, AZ (A.K.)
Boriani, Giuseppe
Autor Boriani, Giuseppe From the Population Health Research Institute, McMaster University, Hamilton, ON (J.S.H., W.F.M., D.C., J.A.W., L.X., K.S., S.N., R.M., S.J.C.), the Montreal Heart Institute, University of Montreal, Montreal (L.R.), the University of Ottawa Heart Institute, Ottawa (D.H.B.), Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Quebec, QC (F.P.), the Department of Clinical Neurosciences, Radiology, and Community Health Sciences, Hotchkiss Brain Institute, University of Calgary, Calgary, AB (S.B.C.), and the Université de Sherbrooke, Sherbrooke, QC (F.A.-P.) - all in Canada the Duke Clinical Research Institute, Duke University, Durham, NC (R.D.L., C.B.G.) Amphia Ziekenhuis, Breda, the Netherlands (M.A.) Oslo University Hospital and the University of Oslo, Oslo (D.A.) the University of Modena and Reggio Emilia, Modena (G.B.), and the Department of Clinical Sciences and Community Health, University of Milan, and the Division of Subacute Care, IRCCS Istituti Clinici Scientifici Maugeri, Milan (M. Proietti) - all in Italy St. George's, University of London, London (A.J.C.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - both in the United Kingdom J.W. Goethe University, University Hospital Department of Cardiology, Frankfurt, Germany (J.W.E., S.H.H.) the Medical University of South Carolina, Charleston (M.R.G.) Michigan State University, Lansing (J.I.) the Institute for Clinical and Experimental Medicine, Prague, Czech Republic (J.K.) the University of Rochester, Rochester, NY (V.K.) Semmelweis University, Budapest, Hungary (V.K.) Karolinska Institutet and the Heart, Vascular, and Neurology Theme, Karolinska University Hospital, Stockholm (C.L.) the University of Rennes, Rennes, France (P.M.) Cliniques du Sud-Luxembourg, Arlon, Belgium (G.M.) Hospital Universitario La Luz, Madrid (J.B.M.), and Hospital Costa del Sol, Marbella (M. Pombo) - both in Spain Aarhus University Hospital and Aarhus University, Aarhus, Denmark (J.C.N.) University Hospital Basel, University of Basel, Basel, Switzerland (C.S.) the Veterans Affairs Portland Health Care System, Portland, OR (I.G.Z.) and Abrazo Arrowhead Hospital, Glendale, AZ (A.K.)
Camm, A John
Autor Camm, A John From the Population Health Research Institute, McMaster University, Hamilton, ON (J.S.H., W.F.M., D.C., J.A.W., L.X., K.S., S.N., R.M., S.J.C.), the Montreal Heart Institute, University of Montreal, Montreal (L.R.), the University of Ottawa Heart Institute, Ottawa (D.H.B.), Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Quebec, QC (F.P.), the Department of Clinical Neurosciences, Radiology, and Community Health Sciences, Hotchkiss Brain Institute, University of Calgary, Calgary, AB (S.B.C.), and the Université de Sherbrooke, Sherbrooke, QC (F.A.-P.) - all in Canada the Duke Clinical Research Institute, Duke University, Durham, NC (R.D.L., C.B.G.) Amphia Ziekenhuis, Breda, the Netherlands (M.A.) Oslo University Hospital and the University of Oslo, Oslo (D.A.) the University of Modena and Reggio Emilia, Modena (G.B.), and the Department of Clinical Sciences and Community Health, University of Milan, and the Division of Subacute Care, IRCCS Istituti Clinici Scientifici Maugeri, Milan (M. Proietti) - all in Italy St. George's, University of London, London (A.J.C.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - both in the United Kingdom J.W. Goethe University, University Hospital Department of Cardiology, Frankfurt, Germany (J.W.E., S.H.H.) the Medical University of South Carolina, Charleston (M.R.G.) Michigan State University, Lansing (J.I.) the Institute for Clinical and Experimental Medicine, Prague, Czech Republic (J.K.) the University of Rochester, Rochester, NY (V.K.) Semmelweis University, Budapest, Hungary (V.K.) Karolinska Institutet and the Heart, Vascular, and Neurology Theme, Karolinska University Hospital, Stockholm (C.L.) the University of Rennes, Rennes, France (P.M.) Cliniques du Sud-Luxembourg, Arlon, Belgium (G.M.) Hospital Universitario La Luz, Madrid (J.B.M.), and Hospital Costa del Sol, Marbella (M. Pombo) - both in Spain Aarhus University Hospital and Aarhus University, Aarhus, Denmark (J.C.N.) University Hospital Basel, University of Basel, Basel, Switzerland (C.S.) the Veterans Affairs Portland Health Care System, Portland, OR (I.G.Z.) and Abrazo Arrowhead Hospital, Glendale, AZ (A.K.)

The New England journal of medicine. 2024 ; 390 (2) : 107-117. [pub] 20231112

N Engl J Med
ISSN 1533-4406
Medvik
Zdroj

BACKGROUND: Subclinical atrial fibrillation is short-lasting and asymptomatic and can usually be detected only by long-term continuous monitoring with pacemakers or defibrillators. Subclinical atrial fibrillation is associated with an increased risk of stroke by a factor of 2.5; however, treatment with oral anticoagulation is of uncertain benefit. METHODS: We conducted a trial involving patients with subclinical atrial fibrillation lasting 6 minutes to 24 hours. Patients were randomly assigned in a double-blind, double-dummy design to receive apixaban at a dose of 5 mg twice daily (2.5 mg twice daily when indicated) or aspirin at a dose of 81 mg daily. The trial medication was discontinued and anticoagulation started if subclinical atrial fibrillation lasting more than 24 hours or clinical atrial fibrillation developed. The primary efficacy outcome, stroke or systemic embolism, was assessed in the intention-to-treat population (all the patients who had undergone randomization); the primary safety outcome, major bleeding, was assessed in the on-treatment population (all the patients who had undergone randomization and received at least one dose of the assigned trial drug, with follow-up censored 5 days after permanent discontinuation of trial medication for any reason). RESULTS: We included 4012 patients with a mean (±SD) age of 76.8±7.6 years and a mean CHA2DS2-VASc score of 3.9±1.1 (scores range from 0 to 9, with higher scores indicating a higher risk of stroke); 36.1% of the patients were women. After a mean follow-up of 3.5±1.8 years, stroke or systemic embolism occurred in 55 patients in the apixaban group (0.78% per patient-year) and in 86 patients in the aspirin group (1.24% per patient-year) (hazard ratio, 0.63; 95% confidence interval [CI], 0.45 to 0.88; P = 0.007). In the on-treatment population, the rate of major bleeding was 1.71% per patient-year in the apixaban group and 0.94% per patient-year in the aspirin group (hazard ratio, 1.80; 95% CI, 1.26 to 2.57; P = 0.001). Fatal bleeding occurred in 5 patients in the apixaban group and 8 patients in the aspirin group. CONCLUSIONS: Among patients with subclinical atrial fibrillation, apixaban resulted in a lower risk of stroke or systemic embolism than aspirin but a higher risk of major bleeding. (Funded by the Canadian Institutes of Health Research and others; ARTESIA ClinicalTrials.gov number, NCT01938248.).

MeSH
antikoagulancia * škodlivé účinky terapeutické užití MeSH
Aspirin * škodlivé účinky terapeutické užití MeSH
cévní mozková příhoda * etiologie prevence a kontrola MeSH
dvojitá slepá metoda MeSH
embolie * etiologie prevence a kontrola MeSH
fibrilace síní * komplikace diagnóza MeSH
inhibitory faktoru Xa škodlivé účinky terapeutické užití MeSH
krvácení chemicky indukované MeSH
lidé MeSH
pyridony škodlivé účinky MeSH
senioři nad 80 let MeSH
senioři MeSH
výsledek terapie MeSH
Check Tag
lidé MeSH
mužské pohlaví MeSH
senioři nad 80 let MeSH
senioři MeSH
ženské pohlaví MeSH
Publikační typ
časopisecké články MeSH
randomizované kontrolované studie MeSH
srovnávací studie MeSH
Geografické názvy
Kanada MeSH

Článek

Studie NOAH-AFNET 6
[NOAH‐AFNET 6 trial]

Ludka, Ondřej, 1974-
Autor Autorita Všeobecná interní klinika LF MU a FN Brno

Remedia. 2024 ; 34 (2) : 131-135.

Remedia (Praha)
ISSN 0862-8947
Medvik
Zdroj

Epizody rychlé frekvence síní (atrial high‐rate episodes, AHRE) jsou síňové arytmie detekované implantovanými srdečními zařízeními. Dosud nebylo známo, zda nás výskyt AHRE u pacientů bez fibrilace síní opravňuje k zahájení antikoagulační léčby. Událostmi řízená dvojitě zaslepená, randomizovaná klinická studie NOAH‐AFNET 6 zahrnula pacienty ve věku 65 let nebo starší, kteří měli AHRE trvající alespoň šest minut a alespoň jeden další rizikový faktor pro vznik cévní mozkové příhody (CMP). Pacienti byli randomizováni v poměru 1 : 1 k podávání edoxabanu nebo placeba. Primární cílový ukazatel účinnosti byl složen z kardiovaskulárního úmrtí, CMP nebo systémové embolie a hodnocen v analýze doby do události. Bezpečnostní cílový ukazatel zahrnoval úmrtí z jakékoliv příčiny nebo velké krvácení. U pacientů s AHRE detekovanými implantabilními zařízeními antikoagulace edoxabanem ve srovnání s placebem významně nesnížila incidenci kardiovaskulárního úmrtí, CMP nebo systémové embolie, ale vedla k vyššímu výskytu úmrtí nebo velkého krvácení. Výskyt CMP byl v obou skupinách nízký.

AHRE (atrial high‐rate episodes) may be detected by implantable cardiac devices. So far, it is not clear whether AHRE unaccompanied by atrial fibrillation mandates the initiation of anticoagulation therapy. In the event‐driven, double blind, randomized clinical trial NOAH‐AFNET 6, patients aged 65 or older with a history of AHRE lasting at least 6 minutes and at least one more risk factor for stroke were investigated. They were randomized 1:1 to edoxaban or placebo. The composite primary endpoint consisted of cardiovascular death, stroke and systemic embolization – time to event was analyzed. All‐cause death and major bleeding represented the safety endpoint. In patients with AHRE detected by implantable cardiac devices, anticoagulation with edoxaban did not ensure significant decrease in the incidence of cardiovascular death, stroke and systemic embolization while it was associated with higher incidence of all‐cause death and major bleeding (compared to placebo). The stroke rate was low in both groups.

Klíčová slova
edoxaban, studie NOAH-AFNET 6,
MeSH
antikoagulancia * klasifikace terapeutické užití MeSH
cévní mozková příhoda etiologie mortalita MeSH
dvojitá slepá metoda MeSH
embolie etiologie mortalita MeSH
fibrilace síní * diagnóza farmakoterapie MeSH
kardiovaskulární nemoci klasifikace mortalita MeSH
lidé MeSH
senioři nad 80 let MeSH
senioři MeSH
srdeční arytmie diagnóza farmakoterapie klasifikace MeSH
srdeční frekvence účinky léků MeSH
Check Tag
lidé MeSH
senioři nad 80 let MeSH
senioři MeSH
Publikační typ
randomizované kontrolované studie MeSH

Článek

Evaluation of the severity of right-to-left shunt in PFO patients after systemic embolism (MEASURE-PFO study): Study design

Kardiologia polska. 2024 ; 82 (7-8) : 774-776. [pub] 20240607

Kardiol Pol
ISSN 1897-4279
Medvik
Zdroj

MeSH
embolie etiologie komplikace MeSH
foramen ovale apertum * komplikace chirurgie diagnostické zobrazování MeSH
lidé MeSH
stupeň závažnosti nemoci MeSH
výzkumný projekt MeSH
Check Tag
lidé MeSH
mužské pohlaví MeSH
ženské pohlaví MeSH
Publikační typ
časopisecké články MeSH

Kapitola

Pooperační komplikace

Chirurgická propedeutika. 2023 ; () : 279-304.

ISBN 978-80-271-3484-7
Medvik
Zdroj

MeSH
chirurgická rána komplikace MeSH
embolie etiologie patologie terapie MeSH
lidé MeSH
nemoci trávicího systému etiologie klasifikace patologie MeSH
pooperační komplikace * etiologie klasifikace terapie MeSH
poruchy hemostázy etiologie klasifikace patologie MeSH
žilní trombóza diagnóza etiologie terapie MeSH
Check Tag
lidé MeSH
Publikační typ
přehledy MeSH

Článek

Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes

The New England journal of medicine. 2023 ; 389 (13) : 1167-1179. [pub] 20230825

N Engl J Med
ISSN 1533-4406
Medvik
Zdroj

BACKGROUND: Device-detected atrial high-rate episodes (AHREs) are atrial arrhythmias detected by implanted cardiac devices. AHREs resemble atrial fibrillation but are rare and brief. Whether the occurrence of AHREs in patients without atrial fibrillation (as documented on a conventional electrocardiogram [ECG]) justifies the initiation of anticoagulants is not known. METHODS: We conducted an event-driven, double-blind, double-dummy, randomized trial involving patients 65 years of age or older who had AHREs lasting for at least 6 minutes and who had at least one additional risk factor for stroke. Patients were randomly assigned in a 1:1 ratio to receive edoxaban or placebo. The primary efficacy outcome was a composite of cardiovascular death, stroke, or systemic embolism, evaluated in a time-to-event analysis. The safety outcome was a composite of death from any cause or major bleeding. RESULTS: The analysis population consisted of 2536 patients (1270 in the edoxaban group and 1266 in the placebo group). The mean age was 78 years, 37.4% were women, and the median duration of AHREs was 2.8 hours. The trial was terminated early, at a median follow-up of 21 months, on the basis of safety concerns and the results of an independent, informal assessment of futility for the efficacy of edoxaban; at termination, the planned enrollment had been completed. A primary efficacy outcome event occurred in 83 patients (3.2% per patient-year) in the edoxaban group and in 101 patients (4.0% per patient-year) in the placebo group (hazard ratio, 0.81; 95% confidence interval [CI], 0.60 to 1.08; P = 0.15). The incidence of stroke was approximately 1% per patient-year in both groups. A safety outcome event occurred in 149 patients (5.9% per patient-year) in the edoxaban group and in 114 patients (4.5% per patient-year) in the placebo group (hazard ratio, 1.31; 95% CI, 1.02 to 1.67; P = 0.03). ECG-diagnosed atrial fibrillation developed in 462 of 2536 patients (18.2% total, 8.7% per patient-year). CONCLUSIONS: Among patients with AHREs detected by implantable devices, anticoagulation with edoxaban did not significantly reduce the incidence of a composite of cardiovascular death, stroke, or systemic embolism as compared with placebo, but it led to a higher incidence of a composite of death or major bleeding. The incidence of stroke was low in both groups. (Funded by the German Center for Cardiovascular Research and others; NOAH-AFNET 6 ClinicalTrials.gov number, NCT02618577; ISRCTN number, ISRCTN17309850.).

MeSH
antikoagulancia * škodlivé účinky terapeutické užití MeSH
cévní mozková příhoda etiologie prevence a kontrola MeSH
dvojitá slepá metoda MeSH
embolie * farmakoterapie etiologie MeSH
fibrilace síní komplikace diagnóza MeSH
implantované elektrody MeSH
inhibitory faktoru Xa * škodlivé účinky terapeutické užití MeSH
krvácení chemicky indukované MeSH
lidé MeSH
rizikové faktory MeSH
senioři MeSH
srdeční arytmie * komplikace diagnóza MeSH
Check Tag
lidé MeSH
mužské pohlaví MeSH
senioři MeSH
ženské pohlaví MeSH
Publikační typ
časopisecké články MeSH
randomizované kontrolované studie MeSH

Článek

Infekční endokarditida s embolizací vegetace do centrální nervové soustavy
[Infective endocarditis with embolization of vegetation into the central nervous system]

Československá pediatrie. 2021 ; 76 (3) : 152-157.

ISSN 0069-2328
Medvik
Zdroj

Infekční endokarditida (IE) je závažné onemocnění s vysokou morbiditou a mortalitou. Častější je u pacientů se strukturální patologií srdce. IE nejčastěji postihuje srdeční chlopně, patologický proces může vzniknout i na nástěnném endokardu nebo na cizích tělesech, která jsou v srdci umístěna. U dětí se strukturálně normálním srdcem patří mezi rizikové skupiny pro vznik IE jedinci s malignitami, nezralí novorozenci, pacienti se zavedeným centrálním žilním katetrem, děti s extrakardiálními strukturálními malformacemi nebo genetickými syndromy a mladí narkomani. Jedno z rizik je embolizace části vegetace do dalších orgánových systémů. Vznik IE je možný i na normálním srdci a bez rizikových faktorů v anamnéze. V kazuistice je demonstrována infekční endokarditida tříletého zdravého dítěte s významnou embolizací do mozku.

Infective endocarditis with embolization of vegetation into the central nervous system Infective endocarditis (IE) is a serious disease with high morbidity and mortality. It is more common in patients with structural pathology of the heart. IE most often affects the heart valves, the pathological process also can affect the wall endocardium or artificial material in the heart. In children with a structurally normal heart, individuals with malignancies, immature neonates, patients with an implanted central venous catheter, children with extracardiac structural malformations or genetic syndromes, and young drug addicts are at risk for developing IE. One of the risks is the embolization of part of the vegetation into other organ systems. IE is possible even in a normal heart and without a history of risk factors. The case report demonstrates the infective endocarditis of a three-year-old healthy child with significant embolization into the brain.

MeSH
antibakteriální látky terapeutické užití MeSH
echokardiografie metody MeSH
embolie etiologie terapie MeSH
endokarditida * diagnóza farmakoterapie MeSH
klinické laboratorní techniky MeSH
lidé MeSH
magnetická rezonanční tomografie metody MeSH
mitrální chlopeň mikrobiologie patologie MeSH
předškolní dítě MeSH
výsledek terapie MeSH
Check Tag
lidé MeSH
předškolní dítě MeSH
ženské pohlaví MeSH
Publikační typ
kazuistiky MeSH

Článek

Iatrogenní embolizace hydrofilních polymerů jako komplikace endovaskulárních výkonů - nová jednotka
[Hydrophilic polymer embolization as an iatrogenic complication of endovascular interventions - a new entity]

Česko-slovenská patologie a Soudní lékařství. 2021 ; 57 (1) : 40-43.

ISSN 1210-7875
Medvik
Zdroj

Iatrogenní embolizace hydrofilních polymerů (HPE – hydrophilic polymer embolization) je málo známou komplikací endovaskulárních výkonů, která může vést až ke smrti pacienta. Incidence tohoto fenoménu není známa. Za časové období osmi měsíců byly retrospektivně zrevidovány vlastní pitvy všech pacientů s anamnézou endovaskulární intervence. Šlo o 10 případů, které byly vyšetřeny histochemicky a v polarizovaném světle. Z těchto 10 případů byla ve 2 prokázána embolizace hydrofilních polymerů. V obou případech se jednalo o embolizaci do plic. Embolizace hydrofilních polymerů je možnou komplikací endovaskulárních vyšetření, na níž je nutno pomýšlet při histologickém hodnocení autoptického materiálu a cíleně po ní pátrat.

Iatrogenic hydrophilic polymer embolization (HPE) is an underrecognised complication of endovascular procedures. In certain instances, HPE and related complications may lead to patiens death. Incidence of this phenomenon is not known. We evaluated retrospectively all autopsies of patients with a history of endovascular intervention performed by one pathology resident during a period of 8 months. There were 10 cases, which were examined histochemically and in polarized light. We detected HPE in 2 of the 10 cases. In both cases the involved organ were lungs. Hydrophilic polymer embolization is a potential and easy-to-miss complication of endovascular procedures. It must be considered during histological examination of autoptic material.

Klíčová slova
iatrogenní embolizace, hydrofilní polymery,
MeSH
embolie etiologie MeSH
katetrizace škodlivé účinky MeSH
lidé MeSH
pitva MeSH
plicní embolie * etiologie MeSH
polymery * škodlivé účinky MeSH
pooperační komplikace etiologie MeSH
retrospektivní studie MeSH
senioři MeSH
smrt MeSH
Check Tag
lidé MeSH
mužské pohlaví MeSH
senioři MeSH
ženské pohlaví MeSH
Publikační typ
kazuistiky MeSH

Kapitola

Embolizace katetrizační chlopně do levé komory

Transkatétrová implantace chlopní v instruktivních kazuistikách. 2021 ; () : 203-213.

ISBN 978-80-7345-676-4
Medvik
Zdroj

MeSH
chirurgická náhrada chlopně škodlivé účinky MeSH
embolie etiologie MeSH
lidé MeSH
selhání protézy MeSH
senioři nad 80 let MeSH
transkatetrální implantace aortální chlopně * MeSH
výsledek terapie MeSH
Check Tag
lidé MeSH
mužské pohlaví MeSH
senioři nad 80 let MeSH
Publikační typ
kazuistiky MeSH

Článek

Intraventricular Thrombus Formation and Embolism in Takotsubo Syndrome: Insights From the International Takotsubo Registry

Arteriosclerosis, thrombosis and vascular biology. 2020 ; 40 (1) : 279-287. [pub] 20191126

Arterioscler Thromb Vasc Biol
ISSN 1524-4636
Medvik
Zdroj

OBJECTIVE: Takotsubo syndrome (TTS) is characterized by acute left ventricular dysfunction, which can contribute to intraventricular thrombus and embolism. Still, prevalence and clinical impact of thrombus formation and embolic events on outcome of TTS patients remain unclear. This study aimed to investigate clinical features and outcomes of patients with and without intraventricular thrombus or embolism. Additionally, factors associated with thrombus formation or embolism, as well as predictors for mortality, were identified. Approach and Results: TTS patients enrolled in the International Takotsubo Registry at 28 centers in Australia, Europe, and the United States were dichotomized according to the occurrence/absence of intraventricular thrombus or embolism. Patients with intraventricular thrombus or embolism were defined as the ThrombEmb group. Of 1676 TTS patients, 56 (3.3%) patients developed intraventricular thrombus and/or embolism following TTS diagnosis (median time interval, 2.0 days [range, 0-38 days]). Patients in the ThrombEmb group had a different clinical profile including lower left ventricular ejection fraction, higher prevalence of the apical type, elevated levels of troponin and inflammatory markers, and higher prevalence of vascular disease. In a Firth bias-reduced penalized-likelihood logistic regression model apical type, left ventricular ejection fraction ≤30%, previous vascular disease, and a white blood cell count on admission >10×103 cells/μL emerged as independent predictors for thrombus formation or embolism. CONCLUSIONS: Intraventricular thrombus or embolism occur in 3.3% of patients in the acute phase of TTS. A simple risk score including clinical parameters associated with intraventricular thrombus formation or embolism identifies patients at increased risk. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01947621.

MeSH
časové faktory MeSH
elektrokardiografie MeSH
embolie diagnóza epidemiologie etiologie MeSH
hodnocení rizik metody MeSH
incidence MeSH
koronární angiografie MeSH
lidé MeSH
magnetická rezonance kinematografická MeSH
míra přežití trendy MeSH
následné studie MeSH
nemoci srdce diagnóza epidemiologie etiologie MeSH
radioisotopová ventrikulografie MeSH
registrace * MeSH
rizikové faktory MeSH
senioři MeSH
srdeční komory MeSH
takotsubo kardiomyopatie komplikace diagnóza MeSH
trombóza diagnóza epidemiologie etiologie MeSH
Check Tag
lidé MeSH
mužské pohlaví MeSH
senioři MeSH
ženské pohlaví MeSH
Publikační typ
časopisecké články MeSH
multicentrická studie MeSH
práce podpořená grantem MeSH
Geografické názvy
Austrálie MeSH
Evropa MeSH
Spojené státy americké MeSH

Článek

Stenting karotických tepen - aktuální informace

Current opinion in cardiology (České vyd.). 2020 ; 13 (1) : 13-17.

Curr. Opin. Cardiol. (Čes. vyd.)
ISSN 1802-3711
Medvik
Zdroj

MeSH
arteriae carotides * chirurgie MeSH
cévy - implantace protéz * metody škodlivé účinky MeSH
embolie etiologie prevence a kontrola MeSH
karotická endarterektomie MeSH
lidé MeSH
pomůcky zabraňující embolii MeSH
stenóza arteria carotis chirurgie etiologie prevence a kontrola MeSH
stenty škodlivé účinky MeSH
Check Tag
lidé MeSH
Publikační typ
přehledy MeSH

Kolekce

Publikováno

Filtry

* Zobrazit nápovědu

* Zobrazit nápovědu

Upřesnit dle MeSH